GAITHERSBURG, Md., Oct. 23 /PRNewswire/ -- MedImmune today announced that researchers will present eight posters from its inflammatory disease program at the Annual Meeting of the American College of Rheumatology, from October 24 to 29, 2008 at the Moscone Center in San Francisco, California.
"MedImmune is working on a number of potential solutions for patients struggling with systemic autoimmune rheumatic diseases," said Barbara White, M.D., vice president, clinical development, respiratory, inflammation, and autoimmunity. "We are pleased to share promising basic research and translational science data relevant to the development of new treatments for diseases such as lupus, rheumatoid arthritis, and myositis"
MedImmune programs that will be discussed include:
-- MEDI-545 - MEDI-545 is a monoclonal antibody (MAb) targeting
interferon-alpha, which regulates processes involved in autoimmune
diseases. MedImmune has launched a broad development program with this
molecule to assess its potential to treat or prevent a variety of
immunological disorders. Currently, MedImmune is conducting a phase 2a
trial in patients with systemic lupus erythematosus (SLE) and a phase 1b
study in patients with active dermatomyositis and polymyositis. The
company has also conducted clinical trials in psoriasis with MEDI-545.
-- CAM-3001 - CAM-3001 is a MAb with potential to help patients with
rheumatoid arthritis. The antibody targets the alpha sub-unit of the
granulocyte-macrophage colony stimulating factor receptor (GM-CSFR).
CAM-3001 is a phase 1 clinical stage program.
-- ICOS - ICOS (Inducible costimulator) is a receptor on activated T-cells
that plays a central role in humoral immunity. Elevated levels of ICOS
are present in patients with autoimmune diseases and effector cytokines
have been shown to corr
Copyright©2008 PR Newswire.
All rights reserved